FH and hemolytic-uremic syndrome: ,3,9 However, since ECU became available in 2009, it has been more commonly used for the treatment of anti-FH antibody–associated HUS, and there is increasing evidence that ECU and immunosuppression without PE could be safely used as a first-line treatment even in children with severe kidney damage.9